WebOverall, these findings suggest the necessity of new clinical studies to further evaluate the efficacy of chemically homogenous batches of mongersen in patients with inflammatory bowel diseases (IBDs), and, at the same time, they can help understand the failure of other clinical trials with antisense oligonucleotides in IBD (i.e. alicaforsen)." Web22 okt. 2014 · Mongersen (GED-0301) from Celgene Corp. (NASDAQ:CELG) produced clinical remission rates as high as 65.1% in a Phase II trial in 166 patients with moderate to severe Crohn’s disease, according to an abstract published in advance of the United European Gastroenterology’s meeting in Vienna.
Impact of patient characteristics on the clinical efficacy of mongersen …
Web4 nov. 2015 · Clinical remission is defined as a CDAI score < 150 and is used to quantify the signs and symptoms of Crohn's disease and the effect on patient's quality of life. It … WebLocation:Pune Duration one week. contact:9962599123🔴🔴 Forwarded as…. Apreciat de Elvira Ioxa. "I am a passionate clinician who is curious and driven to do good for others. Within the Clinical Research team at Thermo Fisher Scientific, I…. Apreciat de Elvira Ioxa. services typing
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial …
Web2 mrt. 2016 · In a phase II trial assessing the efficacy and safety of mongersen, an oral SMAD7 anti-sense oligonucleotide for treating patients with moderate-to-severe active Crohn's disease (CD), 1 remission rates were unprecedented when compared with those reported in pivotal induction studies of biologic therapies in similar population. 2-4 … WebThe primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activity Index (CDAI) score of less than 150, with maintenance of remission for at least 2 weeks, and the safety of mongersen treatment. A secondary outcome was clinical response (defined as a reduction of 100 points or more in the CDAI score) at day 28. WebBackground: A recent phase III trial did not confirm the previous clinical and endoscopic improvements seen in patients with Crohn’s disease (CD) receiving Mongersen, an oral Smad7 antisense oligonucleotide. Factors accounting for such a discrepancy are unknown. services typology